

# Understanding the mechanisms of how behavioural sleep improvement programmes work in young adults with depression and anxiety

<b>Submission date</b> 11/06/2025	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 17/06/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 21/05/2026	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Symptoms of depression and anxiety are common and often distressing. There are reasons to think that poor sleep is an important contributor to depression and anxiety, and if sleep could be improved, depression and anxiety might improve too.

Previous research has shown that we can improve sleep quality using behavioural interventions. While there is evidence that these behavioural treatments improve one's quality of sleep and daytime functioning, it is less clear how they affect the biology of sleep or circadian rhythms (the 'body clock'), especially in people who experience depression and /or anxiety.

In this study we want to compare two behavioural sleep interventions to understand which is more effective in changing sleep, the timing of the body clock, and mental health. Such information may help us develop new and tailored interventions for people with mental health difficulties.

### Who can participate?

People aged between 18 and 40 years who experience depression and/or anxiety and frequent difficulty with falling asleep and/or waking up during the night (insomnia)

### What does the study involve?

Participants are recruited from general practice and the community who experience sleep disruption (insomnia) and either depression or anxiety. GPs will search medical records and send out study invitations. They will also make patients aware of the study during consultations. We will also advertise the study on social media and relevant websites, as well as on posters in GP practices and in communal places around Oxford. People who are interested in taking part in the study will be asked to complete a short questionnaire and a phone interview with a member of the research team to determine if the study is suitable for them. Eligible participants will be allocated at random, by a computer, to one of two behavioural sleep improvement programmes taking place over six weekly sessions. Sleep improvement programme 1 will involve meeting with a trained researcher each week for 6 weeks and following a personalised daily sleep

schedule. Sleep improvement programme 2 will involve meeting with a trained researcher each week for 6 weeks and receiving education and advice on how lifestyle and environmental factors impact our sleep.

All participants will complete assessments at baseline (before the random allocation of treatment), and at 4 weeks, 8 weeks and 26 weeks after random allocation to treatment. This will help us to determine whether the treatments have worked. We will measure symptoms of depression and anxiety using questionnaires. We will measure sleep using questionnaires, sleep diaries, actigraphy (a watch-like device that measures movement), and through measurement of electrical brain activity recorded twice in participants' homes. We will also take a measure of participants' 'biological clock' from samples of saliva, collected in a laboratory, as well as biomarkers of inflammation from blood samples. We will also collect information on medication prescriptions and any other treatments that participants may access during the study.

What are the possible benefits and risks of participating?

Participants may benefit from improved sleep and mental health from taking part in this study. Participants will also contribute to research, which may help develop better treatments for people experiencing mental health problems. Furthermore, all participants who are interested in receiving a summary of the study findings will also be sent a copy of this at the end of the study. We do not anticipate that there are any risks in taking part. However, involvement in the study will involve answering questions about sensitive and potentially upsetting topics. If participants do not feel comfortable answering such questions, the team will discourage them from participating in the study or taking part in the online eligibility questionnaire. There are no known serious side effects from taking part in this study; however, a change to sleep patterns may be associated with a short-term increase in sleepiness. Participants will be informed that if they do feel sleepy during the study, they should avoid activities that require a high degree of vigilance, such as driving or operating heavy machinery.

Where is the study run from?

Nuffield Department of Clinical Neurosciences, University of Oxford (UK)

When is the study starting and how long is it expected to run for?

July 2025 to September 2028

Who is funding the study?

The Wellcome Trust (UK)

Who is the main contact?

Prof. Simon Kyle, [simon.kyle@ndcn.ox.ac.uk](mailto:simon.kyle@ndcn.ox.ac.uk), [spectrum.study@ndcn.ox.ac.uk](mailto:spectrum.study@ndcn.ox.ac.uk)

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Simon Kyle

### ORCID ID

<https://orcid.org/0000-0002-9581-5311>

### Contact details

Sleep and Circadian Neuroscience Institute  
Department of Clinical Neurosciences  
Dorothy Hodgkin Crowfoot Building  
South Parks Road  
Oxford  
United Kingdom  
OX1 3QU  
+44 (0)1865617828  
simon.kyle@ndcn.ox.ac.uk

### **Type(s)**

Public, Scientific

### **Contact name**

Dr Nicola Barclay

### **ORCID ID**

<https://orcid.org/0000-0002-6500-9909>

### **Contact details**

Sleep and Circadian Neuroscience Institute  
Department of Clinical Neurosciences  
Dorothy Hodgkin Crowfoot Building  
South Parks Road  
Oxford  
United Kingdom  
OX1 3QU  
+44 (0)1865 618663  
nicola.barclay@ndcn.ox.ac.uk

## **Additional identifiers**

**Integrated Research Application System (IRAS)**  
350096

**Central Portfolio Management System (CPMS)**  
65265

## **Study information**

### **Scientific Title**

A randomised controlled trial examining the sleep and circadian mechanisms of sleep restriction therapy in young adults with depression and anxiety

### **Acronym**

SPECTRUM

### **Study objectives**

The primary hypothesis is that Sleep Restriction Therapy (SRT) compared to Sleep Hygiene Education (SHE) will increase non-rapid eye movement (NREM) delta power at 8 weeks post-randomisation.

The primary mediation hypothesis is to test if changes in NREM delta power (week 4) mediate improvement in depression and anxiety severity at post-treatment (8 weeks).

### **Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

approved 09/05/2025, City and East Research Ethics Committee (London Centre, London, E20 1JQ, United Kingdom; +44 (0)207 1048171; cityandeast.rec@hra.nhs.uk), ref: 25/LO/0349

### **Study design**

Individual randomized superiority parallel group clinical trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Insomnia and symptoms of mental health difficulties (anxiety and depression)

### **Interventions**

This study will compare two behavioural sleep interventions (sleep improvement programmes) to understand which is more effective at modifying EEG delta power during NREM sleep. Following baseline assessments, participants will be eligible for randomisation. Eligible participants will be randomised (1:1) to Sleep Improvement Programme 1 (79 participants) or Sleep Improvement Programme 2 (79 participants) using a secure, validated and compliant web-based randomisation system (Sortition® - trademarked software from Oxford University Innovation), with a non-deterministic minimisation algorithm to ensure age (18-24 yrs vs. 25-30 yrs), sex (male, female, other), baseline insomnia severity (ISI score: <22 vs. 22-28), depression severity (PHQ-9 score: <20 vs. 20-27), anxiety symptom severity (GAD-7 score: <15 vs. 15-21) and mental health medication (yes, no) are balanced across the two groups. As this trial is not blinded, both the researcher and the participant will know which treatment group they have been allocated to.

Participants randomised to Sleep Improvement Programme 1 will be supported to follow a new personalised sleep schedule, which will be reviewed and adjusted each week. Participants randomised to Sleep Improvement Programme 2 will learn about the science of sleep and be supported with advice on how changing specific lifestyle and environmental factors can improve sleep. Both Sleep Improvement Programmes involve researcher-delivered manualised behavioural intervention over six brief weekly sessions. The six sessions will comprise one in-person session (session 1) and five remote review sessions (2-6), although all sessions could be delivered in-person or remotely if a participant requests this. Participants will be provided with an intervention pack involving an information guide, sleep diaries, and worksheets to guide implementation of the intervention.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Relative NREM Delta power measured using polysomnography at 4 weeks and 8 weeks (primary end-point) after randomisation.

## **Key secondary outcome(s)**

1. In-laboratory timing of circadian phase from Dim Light Melatonin Onset (DLMO) collected from saliva at 8 weeks post-randomisation
2. In-laboratory measure of circadian phase angle from saliva (difference between sleep attempt and DLMO) at 8 weeks post-randomisation
3. Measures of sleep continuity and sleep architecture (EEG variables to include: total sleep time, sleep onset latency, wake after sleep onset, sleep efficiency, absolute values of and proportion of total sleep time spent in stage NREM1, NREM2, NREM3, and REM sleep, NREM3 latency, and sleep-state transition probabilities) measured at 4 and 8 weeks post-randomisation
4. Self-reported depression severity measured using the Patient Health Questionnaire-9 (PHQ-9) at 4, 8 and 26 weeks post-randomisation
5. Self-reported anxiety severity measured using the Generalised Anxiety Disorder 7 (GAD-7) at 4, 8 and 26 weeks post-randomisation
6. Self-reported insomnia severity measured using the Insomnia Severity Index (ISI) at 4, 8 and 26 weeks post-randomisation
7. Sleep-related quality of life measured using the Glasgow Sleep Impact Index (GSII) at 4, 8 and 26 weeks post-randomisation
8. Chronotype measured using the reduced morningness-eveningness questionnaire (rMEQ) at 8 weeks post-randomisation
9. Self-reported pre-sleep arousal measured using the pre-sleep arousal scale (PSAS) at 4, 8 and 26 weeks post-randomisation
10. Cortical arousal measured using pre-sleep and NREM beta power (relative and absolute) derived from polysomnography at 4 and 8 weeks post-randomisation
11. Vigilance assessed hourly during DLMO protocol using the psychomotor vigilance test (PVT) at 8 weeks post-randomisation
12. State sleepiness measured hourly with the Karolinska Sleepiness Scale (KSS) at 8 weeks post-randomisation
13. Mediation analysis: Relative NREM delta power (measured with PSG) at week 4 as a mediator of PHQ-9 and GAD-7 at 8 weeks post-randomisation
14. Mediation analysis: Wake-time after sleep onset (measured with PSG) at week 4 as a mediator of PHQ-9 and GAD-7 at 8 weeks post-randomisation
15. Actigraphy-derived sleep and rest-activity patterns (sleep onset latency [SOL]; Wake-time after sleep onset [WASO]; Sleep efficiency [SE]; Total sleep time [TST]; Relative amplitude [RA]; sleep regularity index, intra-daily variability [IV]; inter-daily stability [IS]; timing of least active 5 [L5] hours and timing of most active 10 hours [M10]), measured at 8 weeks post-randomisation
16. C-reactive protein (CRP) measured from blood drawn at 8 weeks post-randomisation
17. Treatment adherence measured using time in and out of bed derived from mattress sensor, actigraphy and sleep diary during treatment (weeks 1-8 post-randomisation)
18. Regularity, absolute, and threshold levels of light exposure from ambulatory light sensor comparing overall and morning vs evening light, measured at 8 weeks post-randomisation

## **Completion date**

01/09/2028

# Eligibility

## Key inclusion criteria

Current key inclusion criteria as of 26/02/2026:

1. Participant is willing and able to give informed consent for participation in the trial
2. Male or female, aged between 18 and 40 years
3. Participant is able to follow study procedures as laid out in the participant information sheet
4. Sleep efficiency <85% (Pittsburgh Sleep Quality Index [PSQI] items)
5. Screening positive for depressive symptoms on the Patient Health Questionnaire (PHQ-9 [ $\geq 10$ ]) and/or anxiety symptoms on the Generalised Anxiety Disorder assessment (GAD-7 [ $\geq 10$ ])
6. Screen positive for insomnia symptoms on the Sleep Condition Indicator, and meet criteria for insomnia disorder:
  - 6.1. Sleep latency or WASO:  $\geq 30$  mins (Q1 or Q2  $\leq 2$ )
  - 6.2. Frequency of disturbance:  $\geq 3$  nights a week (Q3  $\leq 2$ )
  - 6.3. Sleep quality: average, poor, or very poor (Q4  $\leq 2$ )
  - 6.4. Daytime functioning: Somewhat, much or very much impaired (Q5 or Q6  $\leq 2$ )
  - 6.5. Chronicity of problem:  $\geq 3$  months (Q8  $\leq 2$ )
7. Typical sleep period takes place within the hours of 9 pm and 10 am
8. Currently registered with a GP practice
9. Able to read and understand English
10. Living within the Oxford area to facilitate at-home polysomnographic recordings
11. Has access to a computer, tablet or smartphone and an internet connection at home, or elsewhere, for treatment sessions

---

Previous key inclusion criteria:

1. Participant is willing and able to give informed consent for participation in the trial
2. Male or female, aged between 18 and 30 years
3. Participant is able to follow study procedures as laid out in the participant information sheet
4. Sleep efficiency <85% (Pittsburgh Sleep Quality Index [PSQI] items)
5. Screening positive for depressive symptoms on the Patient Health Questionnaire (PHQ-9 [ $\geq 10$ ]) and/or anxiety symptoms on the Generalised Anxiety Disorder assessment (GAD-7 [ $\geq 10$ ])
6. Screen positive for insomnia symptoms on the Sleep Condition Indicator, and meet criteria for insomnia disorder:
  - 6.1. Sleep latency or WASO:  $\geq 30$  mins (Q1 or Q2  $\leq 2$ )
  - 6.2. Frequency of disturbance:  $\geq 3$  nights a week (Q3  $\leq 2$ )
  - 6.3. Sleep quality: average, poor, or very poor (Q4  $\leq 2$ )
  - 6.4. Daytime functioning: Somewhat, much or very much impaired (Q5 or Q6  $\leq 2$ )
  - 6.5. Chronicity of problem:  $\geq 3$  months (Q8  $\leq 2$ )
7. Typical sleep period takes place within the hours of 9 pm and 10 am
8. Currently registered with a GP practice
9. Able to read and understand English
10. Living within the Oxford area to facilitate at-home polysomnographic recordings
11. Has access to a computer, tablet or smartphone and an internet connection at home, or elsewhere, for treatment sessions

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

## Upper age limit

40 years

## Sex

All

## Total final enrolment

0

## Key exclusion criteria

Current key exclusion criteria as of 21/05/2026:

1. Previously received sleep restriction therapy
2. Currently receiving psychological treatment for insomnia from a health professional or taking part in an online treatment programme for insomnia
3. Another person in the household already participates in this trial
4. Currently taking part in another clinical trial which could affect outcomes in SPECTRUM
5. Currently or recently (within the last 2 months) received inpatient psychiatric treatment
6. Currently taking hypnotic medication that, in the opinion of the investigator, significantly affects sleep.
7. Pregnant/pregnancy planning in the next 6 months
8. Additional sleep disorder diagnosis (e.g., obstructive sleep apnoea) or positive following screening
9. Alcohol or drug-dependent
10. Epilepsy
11. Diagnosis of schizophrenia-spectrum disorder or bipolar disorder, or screening 'positive' for possible bipolar disorder
12. Current suicidal ideation with intent OR attempted suicide within the past 2 months
13. Night, evening, early morning or rotating shift-work, or other uncontrollable sleep disturbances such as caring responsibilities or night feeding
14. Transmeridian travel ( $\geq 2$  time zones) over the past 1 month or planned in the coming 3 months
15. Contraindication to polysomnography such as extremely irritable or sensitive skin on scalp, or allergies to plaster adhesive
16. Any other reason that the investigator deems the participant to be ineligible

Previous key exclusion criteria:

1. Previously received sleep restriction therapy
2. Currently receiving psychological treatment for insomnia from a health professional or taking part in an online treatment programme for insomnia
3. Another person in the household already participates in this trial
4. Currently taking part in another clinical trial which could affect outcomes in SPECTRUM
5. Currently or recently (within the last 2 months) received inpatient psychiatric treatment

6. Currently taking hypnotic medication or other psychotropic medication that, in the opinion of the investigator, significantly affects sleep. Participants who take antidepressant medication and have been on a stable dose will be eligible.
7. Pregnant/pregnancy planning in the next 6 months
8. Additional sleep disorder diagnosis (e.g., obstructive sleep apnoea) or positive following screening
9. Alcohol or drug-dependent
10. Epilepsy
11. Diagnosis of schizophrenia-spectrum disorder or bipolar disorder, or screening 'positive' for possible bipolar disorder
12. Current suicidal ideation with intent OR attempted suicide within the past 2 months
13. Night, evening, early morning or rotating shift-work, or other uncontrollable sleep disturbances such as caring responsibilities or night feeding
14. Transmeridian travel ( $\geq 2$  time zones) over the past 1 month or planned in the coming 3 months
15. Contraindication to polysomnography such as extremely irritable or sensitive skin on scalp, or allergies to plaster adhesive
16. Any other reason that the investigator deems the participant to be ineligible

**Date of first enrolment**

01/07/2025

**Date of final enrolment**

01/03/2028

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre****Sleep and Circadian Neuroscience Institute (SCNI)**

Dorothy Crowfoot Hodgkin Building  
Department of Clinical Neurosciences  
University of Oxford  
South Parks Road  
Oxford  
England  
OX1 3QU

## Sponsor information

**Organisation**

University of Oxford

ROR

<https://ror.org/052gg0110>

## Funder(s)

### Funder type

Charity

### Funder Name

Wellcome Trust

### Alternative Name(s)

Wellcome, WT

### Funding Body Type

Private sector organisation

### Funding Body Subtype

Trusts, charities, foundations (both public and private)

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Dr Nicola Barclay ([nicola.barclay@ndcn.ox.ac.uk](mailto:nicola.barclay@ndcn.ox.ac.uk)) or Prof. Simon Kyle ([simon.kyle@ndcn.ox.ac.uk](mailto:simon.kyle@ndcn.ox.ac.uk))

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>		02/05/2025	16/06/2025	No	Yes
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Participant information sheet</a>	version 3.0	01/01/2026	26/02/2026	No	Yes
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes